und damit eine exklusive, übertragbare Lizenz erworben, die Arbeiten und Patente zum auf der AACR vorgestellten Vorladen von aus Nabelblut gewonnen NK-Zellen mit Affimeds ICE Molekülen zu nutzen.
Soviel geht aus einer SEC Eintragung zur Präsentation der ersten Daten auf der AACR hervor.
Finanzielles
....an upfront license fee payable by Affimed to MD Anderson within thirty (30) calendar days after the entry into the agreement. In addition, MD Anderson is eligible to receive payments for development, regulatory and commercial milestones on a product-by-product basis. Milestone payments include, (i) for AFM13, up to $27 million in development milestones, $52.5 million in regulatory milestones and $90 million in commercial milestones, and (ii) for any other combination product, up to $14.25 million in development milestones, $26.25 million in regulatory milestones and $45 million in commercial milestones. In addition, Affimed shall pay, on a product-by-product basis, for each product sold in any jurisdiction, tiered low single-digit royalties based on net sales of such product sold by Affimed and/or its sublicensees in each calendar year. The Agreement also provides for the payment by Affimed to MD Anderson of a sublicense fee, as well as a portion of the consideration received by Affimed from the sublicensee under the sublicense agreement....